Vanda Pharmaceuticals Inc. VNDA
Set alert
3.88 USD +0.09 +2.37%
At close
3.70 -0.18 -4.64%
Pre-market · Nov 3, 5:53 AM ET
3.70 Day range 3.95
3.70 52-week range 9.94
- YTD
- -56.01%
- 1 year
- -10.80%
- Open
- 3.80
- Prev close
- 3.79
- Mkt cap
- 234.62M
- Vol
- 1.92M
- Avg vol
- 1.07M
- EPS
- -4.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.70
- High
- 3.95
- Forward P/E
- 23.40
- Beta
- 0.77
- Short ratio
- 4.85
- Inst. own
- 78.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 5, 2025
- 50-d avg
- 4.85
- 200-d avg
- 5.03
- 1y target
- 10.43
Analyst view
Consensus: none
Price target (mean) 10.43 +168.8% upside
Now 3.88
- Target (low)
- 5.21
- Target (mean)
- 10.43
- Target (high)
- 18.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
- 2 months ago 4
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 52.25M | +15.4% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 61.02M | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 198.21M | +2.9% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 271.78M | +37.1% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 1, 2024 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Jul 11, 2024 | Cantor Fitzgerald | Initiated | — | Overweight |
| Feb 25, 2022 | Jefferies | Downgrade | Buy | Hold |
| May 12, 2021 | B of A Securities | Initiated | — | Buy |
| Jan 14, 2021 | Citigroup | Downgrade | Buy | Neutral |
| Oct 29, 2020 | Citigroup | Upgrade | Neutral | Buy |
| Jun 9, 2020 | Citigroup | Downgrade | Buy | Neutral |
| Mar 12, 2020 | Citigroup | Upgrade | Neutral | Buy |
| Feb 26, 2020 | Stifel | Maintained | — | Hold |
| Feb 26, 2020 | JMP Securities | Maintained | — | Market Outperform |
| Aug 1, 2019 | Citigroup | Upgrade | Neutral | Buy |
| Jul 25, 2019 | Stifel | Downgrade | Buy | Hold |
| Feb 6, 2019 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Dec 11, 2018 | Stifel | Maintained | Buy | Buy |
| Dec 11, 2018 | Oppenheimer | Downgrade | Outperform | Perform |
| Dec 7, 2018 | Citigroup | Maintained | Buy | Buy |
| Dec 6, 2018 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Dec 4, 2018 | Cantor Fitzgerald | Upgrade | Neutral | Overweight |
| Nov 8, 2018 | Jefferies | Initiated | — | Buy |
| Oct 16, 2018 | Citigroup | Maintained | Buy | Buy |
| Sep 21, 2018 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 14, 2018 | Stifel | Initiated | — | Buy |
| Aug 23, 2018 | Cantor Fitzgerald | Initiated | — | Neutral |
| May 23, 2018 | Citigroup | Initiated | — | Buy |
| Jan 19, 2018 | Seaport Global | Initiated | — | Buy |
| Oct 30, 2017 | Oppenheimer | Maintained | — | Outperform |
| May 26, 2017 | HC Wainwright & Co. | Initiated | — | Buy |
| Apr 12, 2017 | Oppenheimer | Initiated | — | Outperform |